Kintara enrolls final patient in Phase 2 trial of VAL-083 for recurrent GBM

One of California’s leading biopharmaceutical companies, Kintara Therapeutics has reportedly announced enrolling its last patient in its ongoing Phase 2 clinical trial of VAL- 083, a first-in-class, small molecule bifunctional agent that crosses the blood brain barrier.

According to reports, agent has been evaluated in about more than 40 Phase 1 and 2 clinical trials in multiple indications funded by the U.S National Cancer Institute.

The recurrent arm of the study, which is currently being conducted at the MD Anderson Cancer Center in the state, analyzes patients suffering from glioblastoma multiforme (GBM), who have already been pre-treated with TMZ before the disease hit.

Speculations have it that the trial was designed to enroll over 83 patients to know whether the treatment with VAL-083 enhances the overall survival rate or not.

In line with the recurrent arm, the company is also undertaking a second trial which is enrolling up to 36 newly-detected patients who have undergone chemoradiation and surgery with TMZ and are also receiving VAL-083 in place of standard of care TMZ for additional treatment therapy.

It would be pivotal to note that Kintara had in November last year, offered a clinical update on both arms of the study. Through this study, it was quite evident that for the clinical trial, mOS (median overall survival) for the 77 efficacy evaluable patients was somewhere around 7.6 months.

Speaking on the latest move, Kintara’s CEO- Saiid Zarrabian cited that given to the rising need for improved treatment options for the GBM disease, the company is pleased to have reached an important breakthrough of complete enrollment in the recurrent arm of the Phase 2 Clinical study.

He further mentioned that the company would like to extend its heartfelt gratitude to all the patients, their families, and MD Anderson for their participation and constant support for the arm of clinical trial. The final results of the recurrent arm study is expected to be released in Q2 FY2021.

Source Credit: https://www.prnewswire.com/news-releases/kintara-therapeutics-enrolls-final-patient-in-phase-2-clinical-trial-of-val-083-for-recurrent-gbm-301229753.html